Prostate Cancer Screening and Monitoring: The Role of PSA

“Webinar delivered in Spanish with subtitles in Portuguese”

• In 2022, there were approximately 1.4 million new cases of prostate cancer reported globally and over 397,000 deaths reported globally.
• Prostate cancer can be found early in asymptomatic men using a simple, safe, and inexpensive blood test. •
• The most widely used screening tests for prostate cancer include serum total PSA (Prostate Specific Antigen) and digital rectal examination (DRE).
• PSA testing can have significant value in detecting metastatic or persistent disease in patients following surgical or medical treatment of prostate cancer. Persistent elevation of PSA following treatment, or an increase in a post-treatment PSA level is indicative of recurrent or residual disease. PSA testing is widely accepted as an adjunctive test in the management of prostate cancer patients.

• Define the relevance of biomarkers use to diagnose prostate cancer.
• Illustrate the value of PSA to follow up treatment.
• Assess the use of biomarkers as prevention measurement and early diagnoses of prostate cancer.

References:

1. WCRF International. (2024c, June 26). Prostate cancer statistics | World Cancer Research Fund International. Retrieved September 25, 2024, from

https://www.wcrf.org/cancer-trends/prostate-cancer-statistics

2. Can prostate cancer be found early? | How to detect prostate cancer? (n.d.-d). American Cancer Society. Retrieved September 25, 2024, from

https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/detection.html

3. The role of prostate specific antigen measurement in the detection and management of prostate cancer. Endocrinerelated cancer. Nash, A F; Melezinek, DOI:

10.1677/erc.0.0070037